Cormorant Asset Management’s Novavax NVAX Stock Holding History

Cormorant Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-250,000	Closed	-$45.3M	–	120
2021 Q1	$45.3M	Buy	+250,000	New	+$49.8M	1.01%	24
2016 Q3	–	Sell	-80,980	Closed	-$11.8M	–	89
2016 Q2	$11.8M	Buy	80,980 +980	+1%	+$112K	1.67%	23
2016 Q1	$8.26M	Hold	80,000	–	–	1.24%	29
2015 Q4	$13.4M	Hold	80,000	–	–	1.61%	22
2015 Q3	$11.3M	Hold	80,000	–	–	1.81%	18
2015 Q2	$17.8M	Buy	80,000 +18,085	+29%	+$3.18M	2.37%	11
2015 Q1	$10.2M	Sell	61,915 -13,085	-17%	-$2.12M	1.58%	18
2014 Q4	$8.89M	Hold	75,000	–	–	1.37%	24
2014 Q3	$6.25M	Hold	75,000	–	–	1.29%	20
2014 Q2	$6.93M	Buy	75,000 +25,000	+50%	+$2.2M	1.84%	19
2014 Q1	$4.53M	Hold	50,000	–	–	1.04%	33
2013 Q4	$5.12M	Buy	+50,000	New	+$3.53M	1.49%	23

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cormorant Asset Management's NVAX Position: Q2 2021 in Review

Cormorant Asset Management sold out of Novavax (NVAX) in Q2 2021, closing a stake of 250,000 shares — an estimated $45.3M sold.

Cormorant Asset Management first reported a position in NVAX in Q4 2013 and held it in 12 quarters. The position peaked at $45.3M in Q1 2021. 408 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

Cormorant Asset Management reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
Cormorant Asset Management sold 250,000 Novavax shares in Q2 2021, an estimated $45.3M.
Cormorant Asset Management first reported a position in Novavax in Q4 2013 and held it in 12 quarters.
Cormorant Asset Management's Novavax position peaked at $45.3M in Q1 2021.
408 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.